Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Cereno Scientific (Nasdaq First North: CRNO B) ("the Company"), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, announces today that Arena Investors, LP ("Arena") has requested exercise of 600,000 warrants of series 2024/2029, which were issued to Arena in connection with the financing agreement (the "Financing Agreement") being entered into on November 11, 2024. The new Class B shares have been registered the Swedish Companies Registration Office (Bolagsverket). Cereno Scientific receives approximately SEK 4 million.
As part of the Financing Agreement, a total of 5,749,017 warrants of series 2024/2029 were issued to Fenja Capital II A/S and Arena. Each warrant is eligible for subscription of one (1) new Class B-share in the company until 30 April 2029 at a subscription price per Class B-share of 6.82 SEK, subject to customary recalculation principles. Exercise of the warrants can be done during the whole term of the warrants.
Arena has exercised 600,000 warrants corresponding to a total amount of approximately SEK 4 million.
Through the exercise of the warrants, the number of Class B shares in Cereno Scientific is increased by 600,000 Class B shares, from 294,594,861 to 295,194,861 Class B shares, and the share capital is increased by SEK 60,000.00, from SEK 29 531 710,90 to SEK 29,591,710.90. The total number of votes in Cereno Scientific has increased by 600,000 votes, from 301,817,341 to 302,417,341 votes. This corresponds to a dilution effect of approximately 0.20 per cent of the currently outstanding shares in the Company and approximately 0.20 per cent of the currently outstanding votes in the Company. The total number of shares in the Company after the exercise of warrants is 295,917,109, of which 772,248 Class A shares and 295,194,861 Class B shares.
Further information regarding the Financing Agreement can be found in the Company's press releases: Cereno Scientific secures minimum 250 MSEK loan financing to reach set milestones into 2026 (November 11, 2024) and Cereno Scientific secures 100 MSEK through additional loan financing and conversion to advance HDAC inhibitors CS1 and CS014 in Phase II (June 20, 2025).
Completed registration
The Class B shares have been registered with the Swedish Companies Registration Office and the delivery of the Class B shares will be carried out without delay to the custody accounts designated by Arena.
For further information, please contact:
Tove Bergenholt, Head of IR & Communications
Email: tove.bergenholt@cerenoscientific.com
Phone: +46 73- 236 62 46
About Cereno Scientific AB
Cereno Scientific is pioneering treatments to enhance and extend life. The company's innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.
Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals of reverse vascular remodeling and improvement of right heart function as observed in a Phase IIa trial in patients with PAH. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, a new chemical entity with disease-modifying potential, showed favorable safety and tolerability profile in a Phase I trial. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding and pulmonary hypertension.
The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.